Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study

Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and potential effect modification by APOE-epsilon4 carrier status and ethnicity. The MIRAGE Study is a multi-center family stud...

Full description

Saved in:
Bibliographic Details
Published in:BMC geriatrics 2005-01, Vol.5 (1), p.2-2, Article 2
Main Authors: Yip, Agustín G, Green, Robert C, Huyck, Matthew, Cupples, L Adrienne, Farrer, Lindsay A
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - ethnology
Alzheimer Disease - genetics
Alzheimer Disease - prevention & control
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Apolipoprotein E4
Apolipoproteins E - genetics
Female
Heterozygote
Humans
Male
Middle Aged
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and potential effect modification by APOE-epsilon4 carrier status and ethnicity. The MIRAGE Study is a multi-center family study of genetic and environmental risk factors for AD. Subjects comprised 691 AD patients (probands) and 973 family members enrolled at 15 research centers between 1996 and 2002. The primary independent and dependent variables were prior NSAID use and AD case status, respectively. We stratified the dataset in order to evaluate whether the association between NSAID use and AD was similar in APOE-epsilon4 carriers and non-carriers. Ethnicity was similarly examined as an effect modifier. NSAID use was less frequent in cases compared to controls in the overall sample (adjusted OR = 0.64; 95% CI = 0.38-1.05). The benefit of NSAID use appeared more pronounced among APOE-epsilon4 carriers (adjusted OR = 0.49; 95% CI = 0.24-0.98) compared to non-carriers, although this association was not statistically significant. The pattern of association was similar in Caucasian and African Americans. NSAID use is inversely associated with AD and may be modified by APOE genotype. Prospective studies and clinical trials of sufficient power to detect effect modification by APOE-epsilon4 carrier status are needed.
ISSN:1471-2318
1471-2318
DOI:10.1186/1471-2318-5-2